ArticleUrology annals
Circulating microRNAs as biomarker in prostate cancer and their significance in the differentiation of benign and malignant conditions of the prostate.
Article in Urology annals. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- MicroRNAs in Prostate Cancer Liquid Biopsies: Early Detection, Prognosis, and Treatment Monitoring.Cells · 2026Review
- miR-191-5p attenuates TNF-α-induced inflammation in nucleus pulposus cells via targeting EGR1.Journal of orthopaedic surgery and research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Prostate cancer is among the most commonly diagnosed cancers in males worldwide. While Prostate-specific antigen (PSA) remains the front-line screening marker, it lacks sufficient diagnostic accuracy. Aims and Objectives: So, in the quest for improved biomarkers, the expression profiles of circulating miRNAs have become increasingly significant. Hence, this study was undertaken to identify the miRNA profile unique to prostate cancer. Materials and Methods: Using NanoString Human MicroRNA Arrays, we analyzed serum samples from three groups: patients with localized prostate cancer, metastatic prostate cancer, and benign prostatic hyperplasia. Results: Our analysis revealed distinct circulating miRNA expression patterns in prostate cancer patients compared to those with benign conditions. Specifically, miR-1272 and miR-1247-5p were significantly up-regulated (log2FC > 1, p < 0.05), whereas miR-337-3p, miR-191-5p, and let-7a-5p were significantly down-regulated (log2FC < -1, p < 0.05) in prostate cancer versus BPH. Additionally, when comparing localized and metastatic prostate cancer, hsa-miR-302d-3p and hsa-miR-1246 were notably up-regulated (log2FC > 3, Conclusions: Our findings suggest that circulating miRNAs could serve as minimally invasive biomarkers in prostatic cancer with a higher specificity and sensitivity, making them more effective at distinguishing between cancerous and benign conditions. However, despite their promise, miRNA testing remains costly, technically complex, and not yet standardized for routine clinical use. Therefore, further validation in larger, independent cohorts is essential to confirm the diagnostic and prognostic utility of the miRNAs identified in this study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.